PRIMECAP Odyssey Stock Fund
PRIMECAP Odyssey Funds · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
PRIMECAP Odyssey Stock Fund is an actively managed U.S. equity fund. 14% of POSKX’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 81% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
Fund profile
As filed in the prospectus · 2026 Q1
The PRIMECAP Odyssey Stock Fund seeks to provide long-term capital appreciation.
The fund invests primarily in U.S. common stocks selected through fundamental research to identify companies trading at reasonable valuations relative to their growth prospects and profitability, with a three- to five-year investment horizon and no requirement to track an index. The Advisor may maintain significant overweight or underweight positions in particular sectors relative to the S&P 500 and may also invest substantial assets in foreign securities. Because the fund's returns depend on the Advisor's security selection rather than index replication, performance may diverge materially from the S&P 500.
| Share class | Expense ratio |
|---|---|
| POSKX | 0.67% |
Portfolio turnover 9.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 97.82% |
| Cash & short-term | 2.17% |
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Information Technology | 25.6% |
| Industrials | 18.7% |
| Health Care | 16.6% |
| International | 11.3% |
| 9 smaller | 27.7% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Portfolio growth profile
How much of the fund’s stock holdings are in fast-growing companies · as of 2026 Q2
Share of the fund’s equity (by value) in companies whose trailing five-year revenue — or net-income — growth ranks in the top 25% of U.S. public companies. Foreign and newly-listed holdings are excluded, so the figure covers only part of the book. From SEC filings — not investment advice. How we measure this.
Latest quarter
What changed since the fund's previous filing
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| INTC | Intel CorpINTC | 8.17% | $94.48 | $362.68M | 3.8M |
| LLY | Eli Lilly & CoLLY | 4.88% | $934.60 | $216.77M | 231.9K |
| — | AstraZeneca PLC | 3.95% | $187.37 | $175.18M | 934.9K |
| KLAC | KLA CorpKLAC | 3.10% | $1,750.35 | $137.64M | 78.6K |
| — | Flex Ltd | 2.99% | $91.55 | $132.93M | 1.5M |
| FDX | FedEx CorpFDX | 2.51% | $403.31 | $111.56M | 276.6K |
| — | Siemens AG | 2.46% | $296.41 | $109.08M | 368.0K |
| ROST | Ross Stores IncROST | 2.33% | $227.79 | $103.46M | 454.2K |
| BIIB | Biogen IncBIIB | 2.27% | $189.28 | $100.91M | 533.1K |
| MSFT | Microsoft CorpMSFT | 2.26% | $407.78 | $100.29M | 245.9K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.
Top 10 positions are 34.92% of net assets, top 25 56.13%, across 147 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free